Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.

Slides:

Advertisements

Similar presentations

Biochemical Markers for Diagnosis of Myocardial Infarction.

Advertisements

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Myocardial infarction biomarkers Lecture 5. Cases 1 Middle aged man referred by family doctor to a dermatologist because of extensive yellow papules with.

JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.

How can new diagnostic methods contribute in healthcare? What are doctors looking for? Better support in their clinical decision makings, which includes:

Biochemical Markers of Myocardial Infarction

Evaluation of Cardiac Injury and Function. Introduction CHD, – The most important disease affecting the heart is coronary heart disease ACS, – CHD, can.

A view of Novel Cardiac Biomarkers in Heart Failure.

Critical Appraisal DR Joshna Rajbaran. CARDIAC TROPONIN and OUTCOME in ACUTE HEART FAILURE NEJM 358;20 MAY 15,2008.

Amino-Terminal Pro-Brain Natriuretic Peptide, Brain Natriuretic Peptide, and Troponin T for Prediction of Mortality in Acute Heart Failure.

Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the.

Biochemical markers for diagnosis of diseases and follow up Dr. Rana Hasanato Associate professor and consultant Head of clinical chemistry department.

Implementation of a Sensitive Troponin I Assay and Risk of Recurrent Myocardial Infarction and Death in Patients With Suspected Acute Coronary Syndrome.

Biochemical Markers of Myocardial Infarction

The percentage of values for cardiac troponin (cTn)T associated with elevated values for a point-of-care assay with less sensitivity and precision: the.

NTproBNP for the Exclusion of Heart Failure Richard Blakey.

Troponin By Julie Moore C Dt204/2.

The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Utility of B-type natriuretic peptide in the diagnosis.

Cost Containment: Use of Troponin testing in the Inpatient Wards Setting Neal Kaushal, R2 DSR2, May 2013.

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Mariell.

Biochemical Investigations In Heart Disaeses

Biochemical Markers of Myocardial Infarction

Published on – 1 August, 2015 | Number of pages : 103

The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent.

Patient populations by study group figure 10

Biochemical Markers of Myocardial Infarction

Survival probability (%)

BNP in Heart Failure Azam Hadi MD 9/17/2018.

Cardiac Troponin.

Cardiac Biomarkers.

Coronary Artery Disease 2

Biomarkers in Heart Failure

Clyde W. Yancy et al. JACC 2017;70:

The Utility of Biomarkers in Sorting Out the Complex Patient

Cardiac enzymes and cardiac proteins

Part I: A Sensible Approach to Sensitive Troponin

Nat. Rev. Cardiol. doi: /nrcardio

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

Biomarker-Guided HF Therapy: Is It Cost-Effective?

Advancing Acute Coronary Syndrome Assessment:

The Heart Failure Team Heart Failure Care Map First 24 hours.

G. Michael Felker et al. JCHF 2014;2:

Editorial Heart Failure Clinics

Overcoming Clinical Inertia

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Kevin R. King et al. BTS 2016;1:73-86

Nat. Rev. Cardiol. doi: /nrcardio

Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea George A. Alba, MD, Quynh A. Truong,

Perioperative myocardial injury in patients receiving cardiac output-guided haemodynamic therapy: a substudy of the OPTIMISE Trial M.A. Gillies, A.S.V.

High-Sensitivity Troponin in Clinical Practice

Contemporary Considerations in Biomarker-Guided Therapy

Biochemical Markers of Myocardial Infarction

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Copyright © IMARC Service Pvt Ltd. All Rights Reserved Global Cardiac Biomarkers Market Research Report, Trends, Growth, Share, Size and Forecast By 2024.

Michael H. Chiu, MD, Msc, Nakul C. Sharma, MD, MPH CJC Open

Biochemical markers for diagnosis of diseases and follow up

When we compared cardiac volumes (ED and ES) between those with high BNP levels (BNP >400 pg/mL) and low BNP (

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

The Need for Serial Troponin Testing absolute cTn elevations are seen in multiple chronic cardiac and noncardiac conditions rise or fall !! in serial.

Associations of peripartum biomarker levels with e' at 1 month postpartum (PP2). Associations of peripartum biomarker levels with e' at 1 month postpartum.

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Analysis of receiver operating characteristic of three models (model 1: cardiac troponin T (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP),

Spearman’s rank correlation between preoperative serum levels of BNP/NT-proBNP and expression of HIF-2 alpha and preoperative serum level of VEGF. There.

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

Case Study #1. Management of Heart Failure With Comorbidities: Challenging Cases for the Cardiologist.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Study flow chart and diagnosis at discharge from ED

The use of 12 lead electrocardiography and cardiac troponins in the diagnostic evaluation of suspected acute coronary syndrome. *It is unusual to find.

Presentation transcript:

Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome

Cost of Heart Failure to Society

Challenges/Opportunities for Utilizing Biomarkers in the Management of Heart Failure

BNP and NT-proBNP for Diagnosis or Exclusion of Heart Failure

Correlations of Natriuretic Peptides With Cardiac Structure and Function

The Differential Diagnosis of an Elevated BNP or NT-proBNP

BNP and NT-proBNP for Prognosis in Heart Failure

BNP/NT-proBNP and Stage C HF Prognosis

The Importance of Serial NP Measurements for Prognostication in Chronic HF

IMPROVE HR: Improvements in Quality Measures at 24 Months (Patient Level Analysis)

Therapies With Effects on B-Type Natriuretic Peptide Levels

Biomarker-Guided Heart Failure Trials

Understanding Heterogeneous Results in “Guided Therapy” Trials

TIME CHF: Cost Effectiveness

Emerging Uses of Natriuretic Peptides to Guide Therapy

Emerging Biomarkers in Heart Failure

Biomarkers for Detection of Myocardial Infarction

Diagnostic Performance of Sensitive Assays for Troponin

Elevations of Cardiac Troponin Values Because of Myocardial Injury

Elevations of Cardiac Troponin Values Because of Myocardial Injury

Universal Classification of Myocardial Infarction

Universal Classification of Myocardial Infarction (cont)

Prognostic Use of a Sensitive Current Generation Assay for cTn

cTnl Assay Problems

Elevations of Troponins Without Overt Ischemic Heart Disease

Abbreviations

Abbreviations

Abbreviations